ILTOO Pharma

​ILTOO Pharma is clinical-stage French biotech company incorporated in January 2012 as a spin-off of renowned French public institutions: “Assistance Publique des Hôpitaux de Paris” (AP-HP), “Institut National de la Santé et de la Recherche Médicale” (INSERM) and “Université Pierre et Marie Curie” (UPMC).

Its main activity is the repositioning of human recombinant interleukin 2 (rhIL2) following a breakthrough discovery related to its mode of action at low dose. The drug based on this discovery and developed by ILTOO Pharma is named ILT-101.When used at doses 10 to 100 times lower than the ones used in cancer (Proleukin®, Novartis, Chiron), rhIL2 does not stimulate immunity but rather restores self-tolerance by specifically activates cells that regulate immunity, regulatory T cells (Treg).

Autoimmune diseases and inflammatory disorders (AIDs), which are inherently due to functional defect of Tregs, are ideal targets for ILT-101 treatment. In particular, recently diagnosed type-1 diabetes (T1D) and multiple sclerosis (MS) are two priority indications for which there is a high-unmet medical need. In addition, pathologies such as systemic lupus erythematous, Crohn’s diseases or rheumatoid arthritis could also benefited from ILT-101.

On top of that, ILTOO Pharma possesses a deep expertise and extensive know-how in the fields of data mining. This activity supports ILTOO drug development objectives through the identification/confirmation of biomarkers and subsequent stratification of patients’ population according to response to treatment.